Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Shandong First Medical University

Status: Unknown

Conditions: HER2-positive Breast Cancer; Metastatic Breast Cancer

Treatments: Drug: Trastuzumab

Study type: Observational

Funder types: Other

Identifiers

NCT04609540

ShandongCHI-14

Details and patient eligibility

About

To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.

Enrollment: 200 estimated patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• woman, age > 18 years old
• Diagnosed with HER2 +Metastatic Breast Cancer
• Pyrotinib Combined With Trastuzumab And Chemotherapy for at least one cycle, starting from 2020.11.01-2021.10.31
• Available medical history

Exclusion criteria

• Incomplete medical history

Trial design

200 participants in 1 patient group

Pyrotinib and Trastuzumab group

Description:

Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy

Treatment:

Drug: Trastuzumab